MetLife Inc's stock rose by 3.01% and reached a 20-day high amid mixed market conditions, with the Nasdaq-100 down 0.60% and the S&P 500 up 0.06%.
This increase is attributed to MetLife Investment Management being named a '2025 Best Place to Work in Money Management' for the fifth consecutive year. This recognition highlights the company's commitment to a people-first culture and its effectiveness in attracting and retaining talent, which aligns with its growth strategy. The acknowledgment reflects positively on MetLife's reputation in the asset management sector, potentially driving investor confidence.
The implications of this recognition could enhance MetLife's attractiveness to investors, as a strong workplace culture often correlates with better performance and employee satisfaction, which can lead to improved client service and growth.
Wall Street analysts forecast MET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MET is 95.25 USD with a low forecast of 84.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast MET stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MET is 95.25 USD with a low forecast of 84.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 76.260
Low
84.00
Averages
95.25
High
108.00
Current: 76.260
Low
84.00
Averages
95.25
High
108.00
Barclays
Overweight -> NULL
downgrade
$98 -> $90
2026-01-08
Reason
Barclays
Price Target
$98 -> $90
AI Analysis
2026-01-08
downgrade
Overweight -> NULL
Reason
Barclays lowered the firm's price target on MetLife to $90 from $98 and keeps an Overweight rating on the shares. The firm is "cautiously optimistic" on life insurers heading into 2026, saying capital strength, cash flow, and consolidation offset headwinds like spread compression and technology spend. Barclays adjusted ratings and price targets as part of its 2026 outlook.
UBS
downgrade
$95 -> $94
2026-01-08
Reason
UBS
Price Target
$95 -> $94
2026-01-08
downgrade
Reason
UBS lowered the firm's price target on MetLife to $94 from $95.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MET
Unlock Now
Evercore ISI
Outperform -> In Line
downgrade
$108 -> $97
2026-01-06
Reason
Evercore ISI
Price Target
$108 -> $97
2026-01-06
downgrade
Outperform -> In Line
Reason
Evercore ISI downgraded MetLife to In Line from Outperform with a price target of $97, down from $108, and removed MetLife from the Evercore ISI Core List. Despite a solid Q3 earnings print, the downgrade reflects potential downside to forward earnings, relatively high valuation versus mid-cap peers, and pressure from low new-money spreads alongside higher commercial mortgage loan risk, which could hurt both multiples and earnings if credit or commercial real estate conditions worsen, the analyst tells investors in a research note. While additional risk transfer deals could be a catalyst, execution may be delayed as the company appears willing to wait for better pricing, particularly in long-term care where margins and cash flow remain positive.
BofA
Joshua Shanker
Buy
downgrade
$100 -> $98
2026-01-05
Reason
BofA
Joshua Shanker
Price Target
$100 -> $98
2026-01-05
downgrade
Buy
Reason
BofA analyst Joshua Shanker lowered the firm's price target on MetLife to $98 from $100 and keeps a Buy rating on the shares. As in 2025, the pricing trends for most P&C insurance products do not appear positive, the analyst tells investors in a research note. While pricing for liability lines remains positive, it seems that loss costs are rising more steeply than prices, the analyst says, adding that personal auto rates are flattish, while some investors are expecting decline in response to high profitability. The firm added, however, that underwriter valuations hardly look expensive, even as fundamentals have tipped in the "wrong direction."
About MET
MetLife, Inc. is a financial services company, providing insurance, annuities, employee benefits and asset management to individual and institutional customers. Its segments include Group Benefits; Retirement and Income Solutions (RIS); Asia; Latin America; Europe, the Middle East and Africa (EMEA); and MetLife Holdings. Group Benefits segment offers life insurance, dental, group short- and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment insurance, accident and health insurance, and vision, as well as prepaid legal plans and pet insurance. RIS segment provides funding and financing solutions that help institutional customers mitigate and manage liabilities primarily associated with their employee benefit programs using a spectrum of life and annuity-based insurance and investment products. It operates across EMEA in both developed (Western Europe) and emerging (Central and Eastern Europe, Middle East and Africa) markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
